

**MINUTES OF FINANCIAL EVALUATION COMMITTEE MEETING OF TENDER
BMSIC/DRUGS/19-01 (RATE CONTRACT AND SUPPLY OF DRUGS FOR DIFFERENT
HEALTHCARE FACILITIES OF STATE OF BIHAR).**

Date: 28th June 2019

Venue: BMSICL Conference Hall.

The **Financial Evaluation Committee Meeting of Tender No. BMSIC/DRUGS/19-01** was held on 28th June 2019 under the Chairmanship of Managing Director, BMSICL. The other committee members present in the meeting were:

1. Dr. R D Ranjan, Director in Chief, Health Dept., GoB.
2. Sh. Rajani Kant, CGM (Supply Chain), BMSICL.
3. Dr. Ramji Prasad, Principal PMCH, Patna.
4. Sh. Sheo Nandan Prasad, Assistant Internal Financial Advisor (IFA) of Health Dept., GoB (For IFA).
5. Sh. Sunil Kumar Singh, GM (Procurement), BMSICL.
6. Sh. Ramendra Kumar, GM (Finance), BMSICL.

2. The Details of the invited tender are as follows:

1. Tender Reference No. BMSIC/DRUGS/19-01.
2. Tender floated date- 10/01/2019.
3. Last date of submission of online bids- 03/04/2019.
4. Tender Opening date- 08/04/2019.

3. Tender has been floated for 8 (Eight) drugs. It was found in the online opening that total 5 (Five) following bidders have participated in the tender.

1. Ang Life Sciences India Ltd
2. Alpa Laboratories Ltd
3. Bharat Serums and Vaccines Ltd.
4. Plasmagen Biosciences Pvt. Ltd
5. Unicare India Ltd.

4. The summary of bid received status is as follows:

1. No Bid received for 2 Drugs i.e., NIT S1 no. 4 & 5.
2. Single Bid received for 3 Drugs i.e., NIT S1 no. 1, 3 & 6.
3. Multiple Bids received for 3 Drugs i.e., NIT S1 no. 2, 7 & 8.

5. It was unanimously decided in tender opening meeting dated 08.04.2019 to proceed further for technical evaluation for 3 Drugs (NIT S. No. 2,7 & 8) for which multiple bids have been received and re-tender for the remaining 5 Drugs for which single bid (NIT S. No. 1, 3 & 6) and zero bid (NIT S. No. 4 & 5) was received.

6. The Preliminary Evaluation of technical bids of the above-mentioned bidding firms was done by the team of Drug Inspectors deputed at BMSICL. Evaluation sheets were published on the website of BMSICL and Claims/objections were invited vide notice no.880 dated 21.05.2019.



7. After comparison of the clarification received from the bidders in the light of that notice and close examination of the documents submitted by the bidding firms, the drug wise technical evaluation findings by the TEC in its meeting dated 10.06.19 were recorded as follows:

Sl No.	S. N NIT	Name of the Drugs with Specification	Participating Firms	Qualified/ Disqualified	Remarks of TEC
1.	2	Ceftriaxone Injection 250mg	Alpa Laboratories Ltd	Qualified	OK
			Ang Lifesciences India Ltd	Qualified	OK
2.	7	Rabies Immunoglobulin (Human) Injection 150 IU/ml 2 ml Vial/PFS	Bharat Serums and Vaccines Ltd.	Qualified	OK
			Plasmagen Biosciences Pvt. Ltd	Qualified	OK
3.	8	Ceftriaxone Injection 500mg	Alpa Laboratories Ltd	Qualified	OK
			Ang Lifesciences India Ltd	Qualified	OK

8. As M/s Bharat Serums and Vaccines Ltd. & M/s Plasmagen Biosciences Pvt. Ltd are importer firms for the quoted product Rabies Immunoglobulin (Human) Injection 150 IU/ml 2 ml Vial/PFS (NIT Sl no.7). The manufacturing units of the other two bidders i.e. M/s Alpa Laboratories Ltd & M/s Ang Lifesciences India Ltd have been inspected earlier and BMSICL is having valid rate contract with both the firms. It was therefore unanimously decided in that TEC meeting for opening of the financial bids of the above mentioned technically qualified firms for the above-mentioned drugs.

9. Accordingly, in today's meeting financial bids of M/s Ang Life Sciences India Ltd, M/s Alpa Laboratories Ltd Bharat Serums and Vaccines Ltd & M/s.Plasmagen Biosciences Pvt. Ltd were opened online on E-Proc.

10. After opening of the financial bids (downloaded copies annexed as Annexure I) the rates quoted by both the technically qualified bidders were found as following and after comparison of which the bid ranking status is recorded as below: -

Sl No.	S. N NIT	Name of the Drugs with Specification	Participating Firms	Rate as Per Financial Bid	Bid Ranking
				Rate Per unit excluding GST	
1.	2	Ceftriaxone Injection 250mg	Alpa Laboratories Ltd	5.85/-	L1
			Ang Lifesciences India Ltd	7.7/-	L2
	7	Rabies Immunoglobulin (Human) Injection 150 IU/ml 2 ml Vial/PFS	Bharat Serums and Vaccines Ltd.	4150/-	L1
			Plasmagen Biosciences Pvt. Ltd	4380/-	L2

3.	8	Ceftriaxone Injection 500mg	Alpa Laboratories Ltd	8.05/-	L2
			Ang Lifesciences India Ltd	5.69/-	L1

11. It is therefore unanimously recommended by the Financial Evaluation Committee to issue LoI to the L1 declared bidders for the above-mentioned drugs subject to the condition that the L1 declared price must be lower than the NPPA declared ceiling price for each drug.

12. The meeting thus concluded with a vote of thanks.

Sd/-
(Ramendra Kumar)
GM (Finance) BMSICL, Patna.

Sd/-
(Sunil Kumar Singh)
GM (Procurement) BMSICL, Patna.

Sd/-
(Sheo Nandan Prasad)
AIFA, Health Dept. Govt. of Bihar

Sd/-
(Dr. Ramji Prasad)
Principal, PMCH, Patna.

Sd/-
(Rajani Kant)
CGM (Supply Chain), BMSICL, Patna

Sd/-
(Dr. R.D. Ranjan)
Director in Chief, Health Dept.
Govt. of Bihar.

Sd/-
(Sanjaya Kumar Singh)
Managing Director, BMSICL

